Glenmark Pharmaceuticals on Monday said it has launched a medication for prevention of chemotherapy-induced nausea and vomiting, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company. The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.
FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride
Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) announced today that it has submitted to the Japanese Ministry of Health, Labour and Welfare a new drug application for an NK1 receptor antagonist antiemetic drug (development code: Pro-NETU; generic name: fosnetupitant chloride hydrochloride; hereinafter “fosnetupitant”) for gastrointestinal symptoms (nausea and vomiting) associated with cancer chemotherapy.
Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce that the ready-to-dilute liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US.
Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce that the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting (CINV) has been launched in China.
The European Medicines Agency (EMA)’s human medicines committee (CHMP) has recommended five new medicines for approval at its December 2019 meeting, bringing the total tally for the year to 66 recommendations.
AKYNZEO® was developed by Helsinn, and Glenmark has the exclusive marketing rights for the product in India and Nepal under a licensing agreement with Helsinn
Glenmark Pharmaceuticals and Swiss pharma group Helsinn today announced the launch of Akynzeo, a fixed dose combination drug for prevention of chemotherapy-induced nausea and vomiting, in India.